LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - FINANCIALPOST.COM - A La Une - 20/Aug 11:01
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
Health consequences of over active xanthine oxidase may accelerated PKD progression CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance […]
Articles similaires
TC BioPharm to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008 to treat monkey pox
pharmabiz.com - 09/Sep 00:00
TC BioPharm (Holdings) PLC (TC BioPharm), a clinical stage biotechnology company developing platform allogeneic gamma─delta T cell therapies for...
Pan American Energy Announces Completion of Phase 2 Earn-In for Big Mack Lithium Project and Termination of Horizon Property Option
financialpost.com - 29/Aug 20:30
CALGARY, Alberta, Aug. 29, 2024 (GLOBE NEWSWIRE) — Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) (“Pan...
Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market
mountaintoday.in - 07:49
Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...
Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market
mountaintoday.in - 07:49
Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
financialpost.com - 03/Sep 20:34
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
financialpost.com - 03/Sep 20:34
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...
Collegium Pharma acquires Ironshore Therapeutics
pharmabiz.com - 06/Sep 00:00
Collegium Pharmaceutical Inc, a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious...
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
zacks.com - 30/Aug 17:47
HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.
Les derniers communiqués
-
Four Seasons to Expand Saudi Arabian Portfolio Alongside Dar Al Omran Company with New Hotel in Madinah
Four Seasons Hotels and Resorts - 07/05/2024
-
Four Seasons Yachts Unveils Inaugural Itineraries to the Caribbean and Mediterranean and a First Look at its 95 Spectacular Suites
Four Seasons Hotels and Resorts - 27/03/2024
-
Visual 01Elevating Excellence: Four Seasons Embarks on the Next Stage of Strategic Global Growth
Four Seasons Hotels and Resorts - 22/01/2024